INTRODUCTION {#s1}
============

Biology and clinical course of chronic lymphocytic leukemia (CLL) are heterogeneous. An unfavorable prognosis is associated with certain cytogenetic and molecular abnormalities such as del(11q22-q23), *TP53* disruption and un-mutated immunoglobulin heavy-chain variable region (*IGHV*) state \[[@R1]-[@R3]\]. Mutations in RNA-splicing and processing, genes involved in Notch signaling, inflammatory pathway genes and genes in the Wnt pathway are also associated with briefer survival of persons with CLL \[[@R4]\].

Mutations in *SF3B1*, *NOTCH1*, *MYD88* and *BIRC3* are relatively rare in persons of predominately European descent with CLL with frequencies of 5-18%, 8-12%, \~3%, and \~2% \[[@R4]-[@R10]\]. However, mutations of these genes in a sub-clone of CLL cells undetectable by conventional sequencing may become detectable as CLL progresses. It is also likely some new mutations are acquired as CLL progresses with or without therapy \[[@R11]\]. We studied frequencies and prognostic associations of mutations of *SF3B1*, *NOTCH1, MYD88, BIRC3, TP53* and IGHV and cytogenetic abnormalities in 307 Chinese with CLL.

RESULTS {#s2}
=======

Subjects {#s2_1}
--------

Characteristics of the 307 subjects are summarized in Table [1](#T1){ref-type="table"}. Median age was 61 years (range, 16- 92 years) with a male/female ratio of 2:1. Median follow-up is 35 months (range, 1-267 months),

###### Clinical characteristics

                           N (%)
  ------------------------ ----------
  Sex (n=307)              
  Male                     204 (66)
  Female                   103 (34)
  Age (n=307)              
  ≥60                      164 (53)
  \<60                     143 (47)
  Binet (n=297)            
  A                        129 (43)
  B                        70 (24)
  C                        98 (33)
  Disease States (n=307)   
  At diagnosis             166 (54)
  Progressive              88 (29)
  Relapsed                 25 (8)
  Refractory               28 (9)

*SF3B1, NOTCH1, MYD88, BIRC3* and *TP53* mutations {#s2_2}
--------------------------------------------------

307 subjects were studied for *SF3B1* mutations. 15 (5%) had a *SF3B1* mutation. All mutations were missense with p.K700E the most frequent (N=10). 24 of 295 (8%) of subjects analyzed had *NOTCH1* mutations of whom 17 had c.7544-7545delCT. Other mutations were nonsense (N=3) or out-of-frame (N=4). Two mutations, p.L2049fs\*1 and p.Q2404X, were not reported by COSMIC or other studies. Mutations in exons 3-5 of *MYD88* were detected in 23 (8%) of 295 subjects analyzed. The most frequent mutation was p.L265P (N=15). p.V271F is a new mutation. 5 of 238 (2%) had a *BIRC3* mutation including 4 out-of-frame and 1 in-frame. 47 (15%) of 307 subjects analyzed had *TP53* mutations. Most mutations were in the DNA-binding domain (N=45; 94%).

Subjects with *SF3B1* mutation were more likely to have concomitant *TP53* mutation (5 of 15 *vs*. 42 of 292; *P*=0.047). Also, *MYD88* mutations were exclusive of *NOTCH1* and *SF3B1* mutations. Detailed data are presented in [Supplement Table 1](#SD1){ref-type="supplementary-material"}.

IGHV Mutations {#s2_3}
--------------

In 118 of 299 (40%) subjects *IGHV* was germline. The most frequently used *IGHV* genes were *IGHV*4-34 (N=38; 13%), *IGHV*3-23 (N=33; 11%), *IGHV*3-7 (N=30, 10%), *IGHV*4-39 (N=21; 7%), *IGHV*4-59 N=15; 5%), *IGHV*1-69 (n=15; 5%) and *IGHV*3-21 (N=9; 3%).

###### Mutation frequency by disease state

             Diagnosis      Progressive   Relapsed     Refractory
  ---------- -------------- ------------- ------------ -------------
  *SF3B1*    6/166 (4%)     4/88 (5%)     0/25         5/28 (18%)
  *NOTCH1*   4/158 (3%)     9/84 (11%)    4/25 (16%)   7/28 (25%)
  *MYD88*    15/158 (10%)   7/84 (8%)     1/25 (4%)    0/28
  *BIRC3*    2/119 (2%)     1/71 (1.4%)   2/21 (10%)   0/27
  *TP53*     13/166 (8%)    18/84 (21%)   4/25 (16%)   12/28 (43%)

Clinical correlations {#s2_4}
---------------------

*NOTCH1* mutations were detected more frequently in subjects with advanced Binet stages (stage-A, 4 of 126; stage-B: 6 of 66; stage-C, 14 of 94; *P*=0.008). *TP53* mutations were also more common in subjects with advanced Binet stage (stage-A, 11 of 129; stage-B,12 of 70; stage-C, 23 of 98; *P*=0.008). We found no significant correlation between Binet stage and *SF3B1* or *MYD88* mutations (Table [3](#T3){ref-type="table"}) but power to detect an association is limited because of the low frequency of mutations. *MYD88* mutations were less frequent in subjects in whom CD38 was ≥30% (1 of 67 *vs*, 22 of 223; *P*=0.026). *NOTCH1* mutations were associated with CD38 ≥30% but this difference was not significant (9 of 67 *vs.* 15 of 223; *P*=0.081). We found no correlation between *SF3B1* or *TP53* mutations and CD38 ≥30%. There was also no correlation between any of the mutations we studied and ZAP70 ≥20%. *BIRC3* mutations were excluded from this analysis because they were so rare (Table [3](#T3){ref-type="table"}).

*SF3B1*, *NOTCH1* and *TP53* mutations were significantly correlated with germline *IGHV* (*SF3B1,* 10 of 118 *vs.* 5 of 181; *P*=0.027; *NOTCH1*, 21 of 115 *vs.* 2 of 170; *P*\<0.001; *TP53,* 28 of 118 *vs.* 19 of 181: *P*=0.002). In contrast, *MYD88* mutations were more common in subjects with mutated *IGHV* (2 of 115 *vs.* 21 of 172; *P*=0.001; Table [3](#T3){ref-type="table"}). *NOTCH1* mutations were especially common in subjects using *IGHV*4-39 (4 of 19 *vs.* 19 of 268; *P*=0.03) and *IGHV*1-69 (6 of 15 *vs.* 17 of 255; *P*\<0.001). *SF3B1* mutations were correlated with *IGHV*4-59 (4 of 15 *vs.* 11 of 284; *P*=0.004).

###### Associations between subject variables and mutations

                               SF3B1mut      ***P***     NOTCH1mut      ***P***       MYD88mut       ***P***     TP53mut        ***P***
  ------------ --------------- ------------- ----------- -------------- ------------- -------------- ----------- -------------- -----------
  N            307             15/307 (5%)   \-          24/295 (8%)    \-            19/229 (8%)    \-          47/307 (15%)   \-
  Female       103 (34%)       2/103 (2%)    0.089       7/101 (7%)     0.585         6/101 (6%)     0.391       21/103 (20%)   0.093
  Male         204 (66%)       13/204 (6%)               17/194 (9%)                  17/194 (9%)                26/204 (13%)   
  Age          61              61(±12)       0.911       64(±11)        0.212         62(±8)         0.631       61(±13)        0.890
  Binet A      129(43%)        5/129 (4%)    0.305       4/126 (3%)     **0.008**     9/126 (7%)     0.680       11/129 (9%)    **0.008**
  Binet B      70 (24%)        6/70 (9%)                 6/66 (9%)                    4/66 (6%)                  12/70 (17%)    
  Binet C      98 (33%)        4/98 (4%)                 14/94 (15%)                  9/94 (10%)                 23/98 (24%)    
  CD38≥30%     71/302 (24%)    5/71 (7%)     0.356       9/67 (13%)     0.081         1/67 (2%)      **0.026**   10/71 (14%)    0.677
  CD38\<30%    231/302 (76%)   10/231 (4%)               15/223 (7%)                  22/223 (10%)               36/231 (16%)   
  ZAP70≥20%    110/272 (40%)   7/110 (6%)    0.613       11/106 (10%)   0.246         6/106 (6%)     0.523       17/110 (16%)   0.774
  ZAP70\<20%   162/272 (60%)   8/162 (5%)                10/156 (6%)                  12/156 (8%)                23/162 (14%)   
  *IGHV* M     181/299 (61%)   5/181 (3%)    **0.027**   2/172 (1%,)    **\<0.001**   21/172 (12%)   **0.001**   19/181 (11%)   **0.001**
  *IGHV* UM    118/299 (40%)   10/118 (9%)               21/115 (18%)                 2/115 (2%)                 28/118 (24%)   

Association with cytogenetic abnormalities {#s2_5}
------------------------------------------

Cytogenetic abnormalities were common in our subjects including +12 in 59 of 257 (23%), del(17p13) in 42 of 281 (15%) and del(11q22.3) in 40 of 283 (14%). As expected, *NOTCH1* mutations were significantly associated with +12 (9 of 56 *vs.* 12 of 192; *P*=0.020) and *TP53* mutations with del(17p13) (23 of 40 *vs.* 22 of 243; *P*\<0.001). Among the 64 subjects with *TP53* abnormalities, 17 had only del(17p13), 23 had *TP53* mutation and del(17p13) and 22 only *TP53* mutation (2 missed del(17p13) data, but got *TP53* mutation). Surprisingly, there was no correlation between *SF3B1* mutations and del(11q22.3) (4 of42 *vs.* 11 of 239; *P*=0.191). *MYD88* mutations did not correlate with cytogenetic abnormalities ([Supplement Figure 1](#SD1){ref-type="supplementary-material"}). Detailed distribution of mutations and cytogenetic lesions are shown in Figure [1](#F1){ref-type="fig"}.

![Relationship between *TP53, SF3B1, NOTCH1* and *MYD88* mutations, and cytogenetic abnormalities in 307 subjects with data\
Cases which presented with a cytogenetic aberration or a mutation are colored in red. Cohort1: Newly-diagnosed; cohort 2: Progressive; no therapy; cohort 3:Relapsed CLL after therapy; and cohort 4: Refractory, therapy-resistant. Subjects are highlighted in light blue, pink, light green and light purple, respectively. Brown means not analyzed.](oncotarget-06-5426-g001){#F1}

Prognostic relevance of mutations and cytogenetic abnormalities {#s2_6}
---------------------------------------------------------------

We divided subjects into 4 prognostic cohorts: (1) newly-diagnosed; (2) progressive; no therapy; (3) relapsed CLL after therapy; and (4) refractory, fludarabine-resistant. Frequency of gene mutations in each cohort is shown in Table [2](#T2){ref-type="table"}. Mutation rate of *SF3B1* was significantly higher in subjects in cohort 4 (*P*=0.007). *NOTCH1* was less frequently mutated in subjects in cohort 1 (*P*\<0.001) but similar in cohorts 2-4 (*P*\>0.05). *TP53* mutation was less frequent in subjects in cohort 1 (*P*=0.004) and more common in subjects in cohort 4 (*P*=0.033). *MYD88* mutation was more common in subjects in cohort 1 and 2 (*P*\<0.001). There was no significant association of *BIRC3* mutation with any cohort.

Prognostic impact of the abnormalities we studied is shown in Figure [2](#F2){ref-type="fig"}. Survival was significantly briefer in subjects with *NOTCH1* mutation (median, 63 *vs.* 153 months; *P*=0.008), del(11q22.3) (median, 77 *vs.* 152 months; *P*=0.030) and *TP53* disruptions (median, 71 months *vs.* NR, *P*\<0.001). *MYD88* mutations had no significant impact on survival (median, NR *vs.* 142 months; *P*=0.590). However, *SF3B1* mutations had only a borderline impact on survival (median, 70 *vs.* 152 months; *P*=0.055) even when 6 subjects with concurrent *TP53* mutations were included. The frequency of *BIRC3* mutations in *BIRC3* was too low for statistical comparisons ([Supplement Table 2](#SD1){ref-type="supplementary-material"} ).

![Kaplan-Meier curves of survival (a-c) and time-to-treatment (TTT) (d-f) for *SF3B1* (a and d), *NOTCH1* (b and e) and *MYD88* mutations (c and f)](oncotarget-06-5426-g002){#F2}

We divided the *TP53* mutation cohort into 2 cohorts based on *IGHV* rearrangement. 30 of 64 subjects with *TP53* disruption and mutated *IGHV* had longer survival compared with those with *TP53* disruption and germline *IGHV* (median, 141 *vs.* 60 months; *P*=0.001). Survival of the favorable cohort was not significantly different from subjects without *TP53* disruptions (median, 141 months *vs.* NR; *P*=0.308; Figure [3a](#F3){ref-type="fig"}). There was also no significant survival difference with only *TP53* mutation, only del(17p13) or both (*P*=0.474).

Next, we compared whether subjects with *TP53* disruptions and other unfavorable abnormalities including del(11q22.3) or mutations in *NOTCH1* and/or *SF3B1* mutations had shorter survival compared with those with *TP53* disruptions only. There was no significant difference (median, 70 *vs.* 71 months; *P*=0.540; Figure [3c](#F3){ref-type="fig"}). Multiple unfavorable abnormalities were more common in subjects with refractory, fludarabine-resistant disease (cohort 4; 6 of 143 *vs.* 14 of 127; *P*=0.033; [Supplement Table 3](#SD1){ref-type="supplementary-material"}).

The impact of each mutation on TTT was studied in previously untreated subjects (cohort 1 and 2; Table [4](#T4){ref-type="table"}). Subjects with *NOTCH1* mutations and/or *TP53* disruptions had briefer TTT than subjects without these abnormalities (median, 2 *vs.* 57 months; *P*\<0.001 and 12 *vs.* 62 months; *P*=0.003). Subjects with *TP53* disruptions and mutated *IGHV* had similar TTT as subjects without *TP53* disruptions (median: 46 *vs.* 62 months; *P*=0.423). There was no significant correlation between mutations in *SF3B1* or *MYD88* mutation and TTT (median, 14 *vs.* 46 months; *P*=0.586; median, 19 *vs.* 46 months; *P*=0.619; Figure [2](#F2){ref-type="fig"} and [3b](#F3){ref-type="fig"}).

In multivariate analyses variables independently-correlated with TTT included germline *IGHV* (HR=2.30, 95% CI: 1.51--3.49; *P*\<0.001), *TP53* disruptions (HR=1.85, 95% CI: 1.20--2.83; *P*=0.005) and *NOTCH1* mutation (HR=2.17, 95% CI: 1.11--4.23; *P*=0.024).

###### Associations between mutations, cytogenetics, time-to-treatment and survival

                      Time-to-treatment   Survival                         
  ------------------- ------------------- ---------- --------- ----- ----- ---------
  *TP53* disruption   234                            0.003     285         \<0.001
  Yes                 44                  12                   64    71    
  No                  190                 62                   221   NR    
  del(11q22.3)        232                            0.061     281         0.030
  Yes                 28                  18                   42    77    
  No                  204                 47                   239   152   
  +12                 211                            0.393     257         0.366
  Yes                 44                  37                   59    117   
  No                  167                 66                   198   152   
  *SF3B1*             254                            0.586     307         0.055
  Mutated             10                  14                   15    72    
  Wild-type           244                 46                   292   152   
  *NOTCH1*            242                            \<0.001   295         0.008
  Mutated             13                  2                    24    63    
  Wild-type           229                 57                   271   152   
  *MYD88*             242                            0.619     295         0.589
  Mutated             22                  19                   23    NR    
  Wild-type           220                 46                   272   141   

![Kaplan-Meier curves of survival (a) and TTT (b) for *TP53* disruption cases with different *IGHV gene*mutation states\
Comparison of survival subjects with multiple unfavorable alterations including *TP53 vs.* those with *TP53* only mutation is shown in (c).](oncotarget-06-5426-g003){#F3}

DISCUSSION {#s3}
==========

We provide data of frequencies of mutations in *SF3B1*, *NOTCH1*, *MYD88, BIRC3* in Chinese with CLL along with data on previously described prognostic variables including *TP53* disruptions*, IGHV* mutation and cytogenetic abnormalities. One striking difference was the frequency, biological features and prognostic impact of *SF3B1* mutations in Chinese with CLL. The frequency we detected is considerably lower than reported in persons of predominately European descent (Table [2](#T2){ref-type="table"}) \[[@R4], [@R7], [@R8], [@R12]-[@R14]\]. This low rate might be accounted for by the relatively low sensitivity of the Sanger sequencing we used. For example, Jeromin *et al.* reported about 10% *SF3B1* mutations occurred at a mutation load ≤10%, a level detectable only with next generation sequencing (NGS) and would have been missed by us \[[@R13]\]. However, this is unlikely to explain the disparate frequencies we observed. We found *SF3B1* mutation frequency was significantly higher in subjects with advanced, fludarabine-resistant CLL consistent with the notion detection of these mutations result from expansion of a sub-clone of CLL cells and are acquired during disease progression \[[@R15], [@R16]\].

We also found discrepancies regarding to *IGHV* gene use by *SF3B1* mutated cases between our subjects and persons of predominately European descent. Strefford *et al*. reported a much higher frequency of *SF3B1* mutations in stereotyped *IGHV*3-21 \[[@R17]\]. A recent study of 1160 untreated persons of predominately European descent with CLL reported frequent *SF3B1* mutations in subjects with *IGHV*3-21 and *IGHV*1-69 gene use \[[@R13]\]. Many of our subjects had germline *IGHV*. In contrast, *SF3B1* mutations were not correlated with *IGHV*1-69 or *IGHV*3-21 but rather with *IGHV*4-59. This low frequency of *IGHV*1-69 use in Chinese with CLL is previously reported \[[@R18], [@R19]\]. Only 9 of 299 subjects had *IGHV*3-21 use and only 15 used *IGHV*1-69. Furthermore, only one *IGHV*1-69 user had *SF3B1* p.K700E mutation. The reason for the disparities between Chinese and persons of European descent with CLL are unknown and could relate to the low incidence of *SF3B1* mutations and *IGHV*1-69 and *IGHV*3-21 use in Chinese with CLL. It is also possible different antigenic stimuli operate in diverse geographies \[[@R20]\]. Interestingly, *SF3B1* mutation was not associated with advanced Binet stage, CD38 ≥30% or del(11q22.3) but was correlated with *TP53* mutation. These data suggest distinct biological features of *SF3B1* mutated cases of CLL in Chinese may differ from those in persons of predominately European decent.

Incidence of *NOTCH1* mutations in our cohort is relatively low at diagnosis but increased with disease progression. These data are compatible with a sub-clone of CLL cells below the sensitivity of Sanger sequencing followed by clonal expansion during disease course, acquisition of additional mutations spontaneously for as a consequence of therapy or both \[[@R11], [@R16]\]. Mutation detection methods with higher sensitivity, such as allele specific PCR, should be able to distinguish these possibilities which are not mutually-exclusive \[[@R21]\]. The hot spot c.7544-7545delCT deletion accounted for about 70% of our mutated cases. Notably, two novel nonsense mutations were found suggesting the possibility of novel *NOTCH1* mutation sites. Significant associations were observed between *NOTCH1* mutations and advanced Binet stage, germline *IGHV* and +12. *IGHV*4-39 and *IGHV*1-69 were frequently used in subjects with *NOTCH1* mutations. +12 and *NOTCH1*mutations are reported to characterize *IGHV*4-39 CLL belonging to subset 8 and with higher risk of transformation to diffuse large B-cell lymphoma (DLBCL; Richter syndrome) \[[@R22], [@R23]\]. We observed only 1 case of transformation, possibly because of brief follow-up.

Another interesting finding is the high frequency of *MYD88* mutation in our cohort \[[@R12]-[@R14]\]. *MYD88* mutation is common in subjects with mutated *IGHV* and rare in the CD38 ≥30% cohort. Moreover, almost all *MYD88* mutations occurred in untreated subjects consistent with the hypothesis *MYD88* mutation occurs early in CLL development \[[@R11]\]. In addition, we found no significant correlation between *BIRC3* mutation in fludarabine-resistant patients as previously reported \[[@R10]\].

We show *NOTCH1* and *TP53* disruptions are unfavorable factors for survival and TTT consistent with prior studies in persons of predominately European descent \[[@R5], [@R6], [@R8], [@R11]-[@R14], [@R16]\]. In contrast, the prognostic impact of *SF3B1* mutations is modest, if any. The unfavorable impact of *SF3B1* mutation on survival was largely dependent on concurrent mutations in *TP53* and germline *IGHV*. Our data contradict other studies in persons of predominately European descent in whom *SF3B1* mutation is a strong independent predictor of brief survival \[[@R4], [@R7], [@R8], [@R10], [@R11]-[@R16]\]. We had, of course, little power to test the impact of *SF3B1* mutation alone on survival because of the low frequency so our conclusion should be viewed cautiously.

We found high rate of subjects with *TP53* mutations in persons without del(17p13). These subjects had a poor prognosis similar to those with both abnormalities similar to our prior report \[[@R24]\]. However, we also found a cohort of subjects with *TP53* disruptions had stable disease. Subjects with *TP53* disruptions and germline *IGHV* had the worst prognosis whereas those with *TP53* disruptions and mutated *IGHV* gene had longer TTT and survival similar to subjects without *TP53* abnormality. Others report similar data emphasizing the combination of *IGHV* rearrangement and *TP53* disruptions might be a better predictor of prognosis than either variable alone \[[@R14], [@R25]\].

Recently, Greipp *et al.* reported persons with CLL with del(17p13) and del(11q22.3) had briefer survival compared with persons with del(17p13). These persons were termed *double hit* CLL \[[@R26]\]. Based on this report we compared outcomes of persons with *TP53* disruptions and other unfavorable abnormalities including del(11q22.3) or mutations in *NOTCH1* and/or *SF3B1* mutations with those with *TP53* mutation only. We found no significant difference in outcomes. There are several possible explanations for this disparity including different populations, different *NOTCH1* and *SF3B1* mutations and different cut-off values for FISH in the 2 studies. Nevertheless, our data support the concept many unfavorable genetic abnormalities are more common in advanced CLL.

In multivariate analyses, *NOTCH1* mutation, germline *IGHV* and *TP53* disruptions were independently correlated with TTT. Detection of *NOTCH1* mutations helped us reclassify 13 subjects with no other unfavorable risk factors. Patients with *NOTCH1* and/or *SF3B1* mutations were considered intermediate to high risk in other reports \[[@R12]-[@R14]\]. In our cohort *NOTCH1* mutation had the greatest risk of requiring therapy which would also indicate high-risk disease. In contrast, *SF3B1* mutations had little or no prognostic impact and were included in the good-risk cohort. These disparities highlight the need for different risk classifications for different populations with CLL.

In conclusion, we studied frequency and prognostic impact of cytogenetic and molecular abnormalities in a large series of Chinese with CLL and compared these data with data from persons of predominately European descent with CLL. Our study highlights important similarities but also which may offer important clues to the etiology and biology of CLL.

METHODS {#s4}
=======

Subjects {#s4_1}
--------

The study cohort was a single-center consecutive series of 307 Chinese with CLL. Subjects were diagnosed from November, 1991 to April, 2014. Subjects provided informed consent according to institutional guidelines. Diagnosis of CLL was based on International Workshop on CLL-National Cancer Institute (IWCLL-NCI) criteria \[[@R27]\].

Analyses of *SF3B1, NOTCH1, MYD88* mutations and *TP53* disruptions {#s4_2}
-------------------------------------------------------------------

Genomic DNA was isolated from mononuclear cells using the QIAamp DNA Blood Kits (Qiagen, Düsseldorf, Germany) according to the manufacturer\'s recommendation. Direct Sanger sequencing was performed for exon 14-16 of *SF3B1*, PEST domain of *NOTCH1*, exon 3-5 of *MYD88*, exon 6-9 of *BIRC3* and exon 4-9 of *TP53*. Primers are listed in [Supplement Table 4](#SD1){ref-type="supplementary-material"}.

Cytogenetics {#s4_3}
------------

Fluorescence *in situ* hybridization (FISH) analysis was performed on most subjects to detect of del(11q22.3) (n=281), del(17p13) (n=283) and trisomy 12 (n=257). The following fluorescent-labeled probes were used: LSI *ATM* (11q22.3), LSI p53 (17p13) and CEP12 (centromere 12). Probes were purchased from Vysis, Downers Grove, IL, USA. FISH was performed as described \[[@R24]\]. Cut-off levels for positivity were 7.7%, 5.2%, and 3.0% for del(11q22.3), del(17p13) and +12. Although not all subjects with *TP53* mutation were analyzed for del(17p13), we refer the cohort with *TP53* mutation or del(17p13) with no *TP53* mutation testing as *TP53* disruptions.

Immunophenotyping and *IGHV* mutation analyses {#s4_4}
----------------------------------------------

Immunophenotyping of CD38 and ZAP-70 expression and *IGHV* sequencing were performed as described \[[@R28]\]. Positive cut-off values were 30% and 20%. Germline *IGHV* was defined as ≥98% germline homology.

Statistical analyses {#s4_5}
--------------------

Survival was calculated as time from diagnosis until death or last follow-up. Time-to-treatment (TTT) was calculated as time from diagnosis until first treatment. Calculations were performed using SPSS (version 19.0) software (IBM Corporation, Armonk, NY, USA). Categorical variables were compared using χ^2^ test and continuous variables using Student t-test. Survival curves were constructed by Kaplan-Meier method and log-rank test was used for significant associations. Multivariate analysis was done by Cox proportional hazard regression. Multivariate analysis of TTT was done. However, there were too few events to analyze survival. *P*-values were two-sided; *P*\<0.05 was considered significant.
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